logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
INCY
Incyte Corporation
113.81
1 x 113.93
2 x 123.63
bid
ask
+
0.45
0.40%
2 @ 04:00 PM
112.08 -1.73 (1.52%)
Ytd15.23%
1y65.59%
113.31
day range
116.00
66.85
52 week range
116.00
Open115.22Prev Close113.36Low113.31High116.00Mkt Cap22.74B
Vol1.52MAvg Vol1.66MEPS7.08P/E16.07Forward P/E12.32
Beta0.79Short Ratio5.89Inst. Own106.60%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2850-d Avg100.29200-d Avg97.761yr Est111.27

INCY News

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
zacks.com
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS

Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
zacks.com
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average

Incyte: New Catalysts Support Another Leg Higher
seekingalpha.com
Incyte: New Catalysts Support Another Leg Higher

Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a

benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and
benzinga.com
UBS Maintains Neutral on Incyte, Raises Price Target to $113

UBS analyst Ashwani Verma maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price targ

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
gurufocus.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)
benzinga.com
Incyte Announces EMA CHMP Positive Opinion Recommending Approval Of Opzelura Cream For Moderate Atop

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment opt

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
businesswire.com
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults

MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura®
benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $140 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and
benzinga.com
Truist Securities Maintains Hold on Incyte, Raises Price Target to $105

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and rai

Micron To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Micron To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
benzinga.com
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check

benzinga.com
BMO Capital Upgrades Incyte to Market Perform, Raises Price Target to $94

BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perf
benzinga.com
Reported Saturday, Incyte's Phase 3 FrontMIND Trial Shows Tafasitamab Plus Lenalidomide And R-CHOP R

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated h
benzinga.com
Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful
benzinga.com
Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic oss

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
benzinga.com
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential

Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candi
benzinga.com
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $140

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and

benzinga.com
Incyte Strikes Agreement To Acquire Vega Therapeutics For $1.25B

Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Ther
benzinga.com
Mirum Pharmaceuticals And Incyte Announce That Phase 2 Results From The PROGRESS Study Evaluating Zi

The late-breaking rapid-fire presentation will include results from Cohort 1 of the placebo-controll
benzinga.com
Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added T

Incyte (NASDAQ:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evalu